Suppr超能文献

基于网络药理学的西黄丸治疗三阴性乳腺癌干细胞关键机制的鉴定

Network Pharmacology-Based Identification of Key Mechanisms of Xihuang Pill in the Treatment of Triple-Negative Breast Cancer Stem Cells.

作者信息

Zhang Yu-Zhu, Yang Jia-Yao, Wu Rui-Xian, Fang Chen, Lu Hai, Li Hua-Chao, Li Dong-Mei, Zuo Hua-Li, Ren Li-Ping, Liu Xiao-Yuan, Xu Rui, Wen Jia-Huai, Huang Hsien-Da, Hong Ri, Chen Qian-Jun

机构信息

National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.

Breast Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.

出版信息

Front Pharmacol. 2021 Oct 19;12:714628. doi: 10.3389/fphar.2021.714628. eCollection 2021.

Abstract

Xihuang pill, an approved Chinese medicine formula (state medical permit number. Z11020073), is a commonly used adjuvant drug for cancer patients in China. Xihuang pill has a satisfactory effect in treating breast cancer in clinics, especially triple-negative breast cancer (TNBC), which is the most aggressive type of breast cancer, and finite effective therapies. However, the mechanism of Xihuang pill in treating TNBC remains unclear. The present study aims to explore the pharmacological mechanism of Xihuang pill in treating advanced TNBC. We identified the main chemical components of Xihuang pill by using HPLC-Q-TOF-MS/MS. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis shows that serum containing Xihuang pill (XS) had no obvious killing effect on any subtype of breast cancer cells, but it inhibited mammosphere colony formation of two TNBC cell lines (4T1 and HCC1806 cells) and could enhance the inhibitory effect of paclitaxel (PTX) on the proliferation of 4T1 and HCC1806 cells when combined with PTX. Seventy-six active compounds in Xihuang pill, their 300 protein targets, and 16667 TNBC stem cell-related genes were identified. The drug-herb-active compound-target gene-disease network and enrichment analyses were constructed with 190 overlapping candidate targets. Through text mining and molecular docking, the target gene NR3C2 and its active compound naringenin were selected for further validation. According to the TCGA database, we observed that a high expression of NR3C2 promoted a higher survival probability regarding overall survival (OS). experiments indicated that naringenin presented an identical effect to XS, possibly by regulating the NR3C2 expression. Overall, this study explored the effect of Xihuang pill in treating advanced TNBC cells and showed that naringenin, which is the key active compound of Xihuang pill, could lessen the stemness of TNBC cells to produce a synergistic effect on PTX by regulating the NR3C2 gene.

摘要

西黄丸是一种已获批的中药配方(国药准字:Z11020073),在中国是癌症患者常用的辅助药物。西黄丸在临床治疗乳腺癌,尤其是三阴性乳腺癌(TNBC)方面效果良好,三阴性乳腺癌是最具侵袭性的乳腺癌类型,且有效治疗方法有限。然而,西黄丸治疗TNBC的机制尚不清楚。本研究旨在探讨西黄丸治疗晚期TNBC的药理机制。我们使用HPLC-Q-TOF-MS/MS鉴定了西黄丸的主要化学成分。3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)分析表明,含西黄丸血清(XS)对任何亚型的乳腺癌细胞均无明显杀伤作用,但可抑制两种TNBC细胞系(4T1和HCC1806细胞)的乳腺球集落形成,且与紫杉醇(PTX)联合使用时可增强PTX对4T1和HCC1806细胞增殖的抑制作用。鉴定出西黄丸中的76种活性化合物、它们的300个蛋白质靶点以及16667个TNBC干细胞相关基因。利用190个重叠的候选靶点构建了药物-草药-活性化合物-靶点基因-疾病网络并进行了富集分析。通过文本挖掘和分子对接,选择靶基因NR3C2及其活性化合物柚皮素进行进一步验证。根据TCGA数据库,我们观察到NR3C2的高表达促进了总体生存(OS)方面更高的生存概率。实验表明,柚皮素呈现出与XS相同的效果,可能是通过调节NR3C2的表达。总体而言,本研究探讨了西黄丸治疗晚期TNBC细胞的效果,并表明柚皮素作为西黄丸的关键活性化合物,可通过调节NR3C2基因减轻TNBC细胞的干性,从而对PTX产生协同作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b06/8560791/11d5688770a8/fphar-12-714628-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验